LifeMD Shares Rise After Company Offers Novo Nordisk's Wegovy

By Amira McKee

Shares of LifeMD rose after the virtual-healthcare company said it would offer Novo Nordisk's weight-loss pill, Wegovy.

The stock was up 15% at about midday. Shares have risen around 18% year to date.

The U.S. Food and Drug Administration approved the new GLP-1 pill last month. Eligible patients, the New York-based company said Monday, can access the Wegovy pill for as little as $149 per month.

The announcement broadens LifeMD's partnership with Novo Nordisk, the maker of popular GLP-1 injectable Ozempic, LifeMD said. LifeMD is featured on the NovoCare and Wegovy websites as a trusted telehealth provider, it added.

Drug companies and analysts have said the pills could tap in to demand for GLP-1 treatments from patients who would prefer the oral dose over an injection. Pills also cost less to make, offering the prospect of lower prices and better health-insurance coverage than injections do, The Wall Street Journal previously reported.

Wegovy 1.5mg and 4mg pills are available to patients at $149 per month, according to LifeMD. After April 15, Wegovy 4mg pills will be offered at $199 per month, and the 9mg and 25mg doses will be available at $299 per month, the company said.

Write to Amira McKee at amira.mckee@wsj.com

(END) Dow Jones Newswires

January 05, 2026 13:06 ET (18:06 GMT)